In the present study, we explored the potential of Rivastigmine loaded solid lipid nanoparticle (SLN), as a new formulation in improving the bioavailability of Antialzheimer drug Rivastigmine which otherwise reported with poor bioavailability. The "Micrioemulsion based method" was adopted for preparation of SLN. A 3 2 full factorial experiment was designed to study the effect of independent variables such as lipid, surfactant and co-surfactant composition. The formulations were lyophilized to get free flowing powder. The mean particle size of SLN measured to be 137 -1300 nm with PDI value of 0.590 -1.279, and zeta potential value of -3.27 to -27.31 mV was observed which indicates SLN formulations found to more stable. The entrapment efficiency was estimated to be 92.82 -99.80%. SEM study shows SLN in spherical as well as irregular in shape. DSC and FTIR results also confirmed the molecular encapsulation of drug in the lipid matrix. The in-vitro release study shows that all formulations followed Higuchi's Classical Diffusion Model which implies that developed formulations have a potential to deliver the drug in controlled release manner. These finding explore the potential of proposed SLN of rivastigmine formulation as an alternative drug delivery system in improving bioavailability of Rivastigmine.